Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions
- Conditions
- ClaudicationSuperficial Femoral Artery StenosisIschemic Leg
- Registration Number
- NCT04434586
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
This is a common care study. A study for evaluating the quality of balloon inflation and stent application will be performed in 2D angiography alone in the control group and then by 2D and OCT angiography for the experimental group. The benefit could be an improvement in the results of revascularization of femoropopliteal lesions thanks to OCT which allows a 3D visualization of the arterial lumen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 166
- Patient over 18 years old
- Femoral-popliteal lesion TASC-C or TASC-D de novo (F1 to P1)
- Starting lesion on the superficial femoral artery and not extending beyond the intercondylar notch (P2)
- ≥1 continuous permeable leg axis directly injecting the plantar arch
- Rutherford 2-5
- Patient under personal protection regime (tutorship, guardianship)
- Absence of arterial axis in permeable leg
- Patient presenting a limb acute ischaemia (chart evolving since less than 14 days)
- Patient without favorable element to consider healing
- History of stents on the femoropopliteal axis
- History of femoropopliteal bypass
- Untreated stenosis ≥30% on the iliac axis and common femoral upstream
- Popliteal lesion beyond the intercondylar notch (P2)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Primary patency rate at 1 year. at 12 months (+/- 2months) The permeability rate is defined by the echodoppler criteria: PVS\>2.4m/s or appearance of stenosis on the previously treated segment \>70%.
- Secondary Outcome Measures
Name Time Method Target vessel revascularisation at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months) corresponds to the occurrence of a re-intervention on the previously treated artery, whatever the level, in order to maintain its permeability.
Primary patency rate at 1 year. at 1month (+/- 10days), 6months (+/- 1month) Target lesion revascularisation at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months) corresponds to the occurrence of a re-intervention on the treated segment to maintain or restore permeability
cost-effectiveness analyses at 12 months (+/- 2months) Cost-effectiveness analysis between 2 therapeutic strategies: The costs related to each strategy are calculated taking into account the direct and indirect costs.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Insitut Coeur-Poumon, CHU
🇫🇷Lille, France
Insitut Coeur-Poumon, CHU🇫🇷Lille, FranceJonathan SOBOCINSKI, MDPrincipal Investigator